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Abstract
Background: opioid and somatostatin receptors (SSTRs) that can assemble as heterodimer were
individually reported to modulate malignant cell proliferation and to favour apoptosis. Materials and
methods: SSTRs and opioid receptors expression were examined by RT-PCR, western-blot and
binding assays, cell proliferation was studied by XTT assay and propidium iodide (PI) staining and
apoptosis by annexin V-PI labelling.
Results: almost all human malignant haematological cell lines studied here expressed the five
SSTRs. Further experiments were conducted on the human U266 multiple myeloma cells, which
express also μ-opioid receptors (MOP-R). XTT assays and cell cycle studies provide no evidence
for a significant effect upon opioid or somatostatin receptors stimulation. Furthermore, neither
direct effect nor potentiation of the Fas-receptor pathway was detected on apoptosis after these
treatments.
Conclusion: these data suggest that SSTRs or opioid receptors expression is not a guaranty for
an anti-tumoral action in U266 cell line.
Background
Multiple myeloma (MM) is a malignant hemopathy
caused by the accumulation of slow proliferating and
apoptosis-resistant cells in the bone marrow [1]. This
pathology represents 10% of haematological malignan-
cies [2] and accounts for 2% of cancer deaths per year in
occidental countries [3]. Interactions between MM and
the bone-marrow environment play a major role in the
development of the disease and resistance to therapies [4].
Such interactions involve integrins and adhesion mole-
cules which promote cytokines and growth factors release.
After binding to their respective receptors, these factors
activate diverse signal transduction pathways: MAPK
(Mitogen-Activated Protein Kinase), JAK (Janus kinase)/
STAT3 (signal transducers and activators of transcription)
and PI3K (Phosphoinositide 3-kinase)/Akt), leading to
apoptosis resistance, survival and proliferation [4]. Thus,
pharmacological modulation of such pathways would
represent complementary therapeutic strategies to con-
ventional treatment for MM, which still remains incura-
ble.
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Somatostatin (Sst) is a small neuropeptide acting through
a family of five G protein-coupled receptor (GPCR) sub-
types 1–5 (SSTR1-5), which are expressed in lymphoid
cells, the nervous and gastro-entero-pancreatic systems [5-
7]. Autoradiography analysis using iodinated Sst analogs
revealed that central and peripheral lymphoid organs
express SSTRs [8], data that were further confirmed by RT-
PCR (see for review [9]). Beside its physiological func-
tions, Sst was revealed as a potent anti-tumoral agent,
especially in neuroendocrine tumours [10,11]. For
instance, protease-resistant Sst analogs such as octreotide
have been successfully used for tumours treatment
[11,12]. Other GPCRs than SSTRs [13-15] such as opioid
receptors were demonstrated to be expressed in the
immune system, to have an anti-tumoral activity [16] and
to heterodimerize with SSTRs [16,17]. So, in the present
study, we evaluated the potential role of somatostatin and
opioid receptors in the regulation of cell proliferation and
apoptosis in malignant hemopathies.
Methods
Cell culture
Except for the SK-N-BE and MCF-7 cells, that were cul-
tured in Dulbecco's modified Eagle's medium (DMEM)
(Sigma-Aldrich, St Louis, MO), supplemented with 10%
(v/v) foetal calf serum (FCS) (BioWest), 1% (v/v) antibi-
otic-antimycotic mixture (Sigma, St Louis, MO), and 2
mM L-glutamine, the other cell lines were grown in RPMI
1640 + GlutaMAX (Invitrogen) supplemented with 10%
(v/v) FCS and 1% (v/v) antibiotic-antimycotic mixture, all
maintained at 37°C in 5% CO2. Twice a week, cells were
counted, the viability was determined using trypan blue
staining and the culture medium was replaced.
RT-PCR
Total RNAs were extracted using the RNAgents® Total RNA
Isolation System (Promega) according to Chomczynski
and Sacchi [18]. cDNAs were synthesized from 2 μg of
RNA in a buffer supplied with the reverse transcriptase
(RT) (Promega) containing 900 μM dNTP (Amersham),
20 units RNAsine (Promega), 500 ng random primers
(Promega) and 200 units of Moloney murine leukaemia
virus RT in a final volume of 20 μL. PCRs were performed
using 2 μL of cDNAs in the PCR buffer supplied with the
Taq polymerase supplemented with 1.5 mM MgCl2, 0.2
mM of dNTP, 2.5 units of Taq polymerase (Bioline), and
0.5 μM of each sense and antisense primer. Primers for
SSTR1, 2 and 3 were chosen from a previous study [19],
primers for SSTR4 and 5 and opioid receptors (KOP-,
DOP- and MOP-R) were designed using primer 3 input
[20]. Their sequences are listed in Table 1. PCR products
were run on a 1.5% agarose or 2% NuSieve® agarose gel
Table 1: Primers used for SSTRs, opioid receptors and β-actin amplification by PCR
Gene name Primers Cycles Denaturation step Elongation step Anneling step
β-actin F – 5'ATGGATGATGATATCGCCGCG3'
R-5'TCCAGACGCAGGATGGCATGG3'
35 1 min at 95°C 1 min at 72°C 1 min at 60°C
SSTR1 F-5'AGCCGGTTGACTATTACGCC3'
R-5'GCTCTCACTTCTACCATTGTC3'
45 1 min at 95°C 2 min at 72°C 1 min at 60°C
SSTR2 F-5'GGTGAAGTCCTCTGGAATCC3'
R-5'CCATTGCCAGTAGACAGAGC3'
45 30 sec at 95°C 2 min at 72°C 1 min at 63°C
SSTR3 F-5'TCATCTGCCTCTGCTACCTG3'
R-5'GAGCCCAAAGAAGGCAGGCT3'
45 30 sec at 95°C 2 min at 72°C 1 min at 65°C
SSTR4 F-5'CACCAGCGTCTTCTTCTCA3'
R-5'ATGGGGAGAGTGACCAACAG3'
35 1 min at 95°C 1 min at 72°C 1 min at 55°C
SSTR5 F-5'TCATCTGCCTGTGCTACCTG3'
R-5'GGAGAGGATGACCACGAAGA3'
35 1 min at 95°C 1 min at 72°C 1 min at 55°C
MOP-R F-5'CAATGCAGAAGTGCCAAGAA3'
R-5'CAAGATGAAGACTGCCACCA3'
45 30 sec at 95°C 1 min at 72°C 1 min at 56°C
KOP-R F-5'AAGGAGCACTCAATGAC3'
R-5'CAGCATCTTCACCTTGACCA3'
35 1 min at 94°C 1 min at 72°C 1 min at 55°C
DOP-R F-5'GGACGCTGGTGGACATC3'
R-5'GGATCCCGTCTCCGAAACA3'
40 30 sec at 96°C 1 min at 72°C 30 sec at 58°C
Primers (F, forward and R, reverse) used for amplification of SSTRs, opioid receptors and β-actin genes and PCR conditions are indicated.Journal of Experimental & Clinical Cancer Research 2009, 28:77 http://www.jeccr.com/content/28/1/77
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with a 100 bp marker (Invitrogen) and stained with ethid-
ium bromide.
Radioligand binding experiments
U266 cells were harvested by centrifugation (100 g, 5
min). The resulting pellet was resuspended in 50 mM Tris-
HCl, pH 7.4 and disrupted with a Polytron (5 × 3 sec) at
4°C. The homogenate was ultracentrifuged at 100.000 g
during 35 min at 4°C. Then, the pellet was resuspended
in 50 mM Tris-HCl, pH 7.4 by sonication, protein concen-
tration was determined by the Bradford method using
bovine serum albumin (BSA) as standard and the
homogenate was ultracentrifuged as before. The final pel-
let, which corresponds to the crude membrane fraction,
was dispersed by sonication in binding buffer (50 mM
HEPES, 5 mM MgCl2, 1 mM CaCl2, 0.2% (w/v) BSA, pH
7.4 for [125 I-Tyr0] somatostatin (Phoenix Pharmaceuti-
cals) binding or in 50 mM Tris-HCl, pH 7.4 for
[3H]diprenorphine (NEN PerkinElmer) binding) at a final
concentration of 4–6 mg/mL. Proteins (200–300 μg) were
incubated with desired concentrations of the radioligand
(from 0.01 to 0.5 nM of [125 I-Tyr0] somatostatin and from
0.5 to 20 nM of [3H]diprenorphine) in the absence (total
binding) or in the presence of cold cyclo [7-aminohep-
tanoyl-Phe-DTrp-Lys-Thr(Bzl)] (100 nM cyclosomatosta-
tin) or levorphanol (50 μM) (nonspecific binding) during
30 min at 37°C in 250 μL of binding buffer. Samples were
then rapidly filtered on glass-fiber discs (Whatman GF/B)
and washed twice with 1 mL of ice-cold washing buffer for
[125 I-Tyr0] somatostatin (500 mM NaCl, 0.1% (w/v) BSA,
pH 7.4) or 10 mM Tris-HCl, pH 7.4 for [3H]diprenor-
phine. Bound radioactivity was measured in a scintillation
counter. All experiments were carried out in duplicate
(SSTR binding) or in triplicate (opioid receptor binding)
and repeated at least three to four times.
Western blot analysis
Cells were harvested by centrifugation (100 g, 5 min) and
the resulting pellet was suspended in lysis buffer (10 mM
Tris-HCl, 1 mM EDTA, 0.1% (v/v) Triton-X100, pH 7.4)
and sonicated at 4°C. Supernatants were cleared by cen-
trifugation (20.000 g, 20 min at 4°C) and protein concen-
trations were determined by the Bradford assay. Equal
amounts of proteins were resolved on 10% (w/v) acryla-
mide gels by SDS-PAGE and transferred onto a nitrocellu-
lose membrane. After incubating for 1 h in blocking
buffer (phosphate-buffered saline (PBS), 5% (w/v) nonfat
dry milk or PBS, 0.1% (v/v) Tween-20 (PBS-T), 5% (w/v)
nonfat dry milk), membranes were immunoblotted with
a 1:1000 dilution of rabbit anti-KOP-R (Abcam) or anti-
DOP-R (Oncogene) or with a 1:2000 dilution of the rab-
bit anti-MOP-R (Abcam) antibody overnight at 4°C. After
washing in PBS or PBS-T, nitrocellulose sheets were incu-
bated with a 1:2000 dilution of peroxidase-conjugated
anti-rabbit IgG (Sigma Aldrich) for 3–4 h in the blocking
buffer. Opioid receptors were revealed using the enhanced
chemiluminescence system (PerkinElmer Life Sciences)
with human placenta, SK-N-BE and SH-SY5Y cells as pos-
itive controls.
Cell viability assay
Cell viability was determined using CellTiter 96® AQueous
One Solution Cell Proliferation Assay (Promega) accord-
ing to the manufacturer's instructions. All experiments
were done in culture medium containing FCS. The day
before agonist treatment, cells were allowed to proliferate
in fresh culture medium. After assuring that the viability
was more than 90%, cells were seeded at a density of 3 ×
104 cells/well in 96-well microtiter plates. U266 cells were
exposed or not (control) in the presence of various con-
centrations of octreotide (Oct) or Sst alone or combined
with their antagonist cyclosomatostatin (Css) at 10 μM for
various times (24, 48 or 72 h). Cells were also treated with
a combination of Sst and morphine (opioid agonist).
Each condition was realised in triplicate and compared to
control cells performed in sextuplet. The optical densities
were measured at 492 nm and corrected by subtracting the
average absorbance from wells containing cell-free
medium (blank). Results are normalised compared to
control cells and the percentage of viable cells is expressed
according to the following formula: ((ligand treated cells
- blank)/(control cells - blank)) × 100.
Apoptosis and cell cycle analysis
U266 cells were prepared as described above except that
cells were seeded into 6-well plates at a density of 6 × 104
cells/well. In order to observe a putative potentiation of
apoptosis with SSTRs, U266 cells were pretreated or not
(control) with 0.1 ng/mL of the agonistic Fas antibody
7C11 alone or combined with Sst or Oct for 24, 48 or 72
h.
For the cell cycle analysis, cells were pelleted by centrifu-
gation (100 g, 5 min) and fixed in 80% (v/v) ice-cold eth-
anol and the pellet was incubated in phosphate-buffered
saline (PBS) containing 100 μg/mL RNAse A (Qiagen)
and 20 μg/mL PI (Sigma-Aldrich) for 30 min at 37°C. Cell
sorting was performed using the Epics Altra (Beckman
Coulter). Gated events (2 × 104), except doublets and
aggregates, were acquired for each sample and the results
were analyzed with Wincycle® software.
For apoptosis detection, cells were pretreated or not (con-
trol) as described above for cell cycle analysis. At the end
of the treatment, cells were rapidly centrifuged and apop-
tosis was assessed using AnnexinV-FITC Apoptosis Detec-
tion Kit II "AnnexinV-PI" (BD Pharmingen) as described
by the manufacturer. Samples were analysed on Epics
Altra (Beckman Coulter).Journal of Experimental & Clinical Cancer Research 2009, 28:77 http://www.jeccr.com/content/28/1/77
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Statistical Analysis
All results are expressed as the mean ± S.E.M of n experi-
ments. ANOVA followed by the Bonferroni-Dunn test was
used to determine the statistical significance (Statview®).
Results
Expression of SSTRs and opioid receptors in malignant 
hemopathy cell lines
To investigate SSTRs and opioid receptors expression in
various malignant haematological cell lines, total RNA
extraction was performed from the pre-B leukaemia cell
lines 697 and Nalm6, the MM cell lines RPMI-8226,
U266, LP-1, NCI-H929, the Burkitt lymphoma cell line
Ramos and the T lymphoma cell line Jurkat, followed by
RT-PCR. The human neuroblastoma cell line SH-SY5Y
and the breast carcinoma cell line MCF-7 were used as
positive controls for SSTRs expression [21,22]. The ubiq-
uitously expressed β-actin gene was used as control (Fig-
ure 1A). The PCR for SSTR1 was positive in all cell lines
but doublet PCR products could be detected in Jurkat,
NCI-H929, 697 and U266 cell lines (Figure 1B) as previ-
ously described in hepatocellular carcinoma [23]. When
examining SSTR2 mRNAs expression, we found the pres-
ence of a single band in all cell lines and in SH-SY5Y and
MCF-7 cells (Figure 1C). SSTR3 mRNAs were detected in
Jurkat, Nalm6, RPMI-8226, Ramos, NCI-H929, LP-1 and
U266 (Figure 1D) while the two other SSTR subtypes were
amplified in all cell lines that we examined (Figure 1E and
1F). As a preliminary work performed on U266 cells sug-
gested that they contain opioid receptors, we further char-
acterised their subtypes. In the U266 cells, we were able to
detect mRNAs encoding for the DOP- and MOP-R but not
KOP-R while all the three opioid receptors were observed
in the SH-SY5Y cells (Figure 1G). It's worthy to note that
several bands were amplified in U266 cell line for MOP-
R, probably reflecting the presence of alternative splicing
of this gene as previously reported [24]. In western-blot
experiments, MOP-, DOP- and KOP-R were detected in
positive controls (SH-SY5Y, SK-N-BE and human pla-
centa, respectively) [25-28] whereas only the MOP-R was
evidenced in U266 cells (Figure 1H). Furthermore, SSTRs
and opioid receptors were also revealed by using their
ability to bind their prototypic ligands, [125 I-Tyr0] soma-
tostatin and [3H]diprenorphine, respectively (Table 2).
Thus, the U266 cell line represents a suitable model for
exploring putative interactions between somatostatin and
opioid receptors to modulate cellular proliferation and
apoptosis [29-33].
Effect of SSTR and opioid agonists on U266 cell viability
Cell viability was then evaluated using XTT assays. All
experiments were done in culture medium containing
FCS. U266 cells were treated or not (control) in the pres-
ence of either Sst or Oct, a SSTR2, 3 and 5 selective agonist
[6,34], ranging from 100 pM to 10 μM during 24, 48 or 72
h. As depicted on the Figure 2A, Sst, even at high concen-
trations, was devoid of any significant effect on cell viabil-
ity at 24, 48 or 72 h pretreatment. When cells were
exposed to a selective SSTR antagonist, cyclosomatostatin
(Css), alone or in combination with Sst, no significant
effect was detected. Stimulation of SSTR2, 3 and 5 by Oct
(100 pM to 10 μM) alone or in combination with 10 μM
of Css for 24, 48 or 72 h was unable to promote any sig-
nificant modification of cell viability (Figure 2B).
Next, we evaluated the potential interactions between opi-
oid and somatostatin receptors. U266 cells were exposed
or not (control) either to Sst alone, to a combination of
Sst plus 10 μM morphine (Morph) or Css, but still no
modification of U266 cell viability was noted after 24, 48
or 72 h (Figure 2C).
Table 2: U266 cells express opioid and somatostatin binding sites.
[Diprenorphine] (nM) CPM [Somatostatin] (nM) CPM
0,5 44 ± 32 0,025 139 ± 66
1 127 ± 84 0,05 506 ± 313
2,5 157 ± 90 0,076 628 ± 92
5 197 ± 78 0,1 677 ± 326
10 552 ± 276 0,25 987 ± 483
20 2746 ± 1382 0,5 2464 ± 869
Crude membrane fraction was incubated with [125I-Tyr0] somatostatin or [3H]diprenorphine as described in materials and methods. Data represent 
mean ± S.E.M. (n = 3–4) of specific binding expressed in CPM.Journal of Experimental & Clinical Cancer Research 2009, 28:77 http://www.jeccr.com/content/28/1/77
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Expression of SSTRs and opioid receptors in malignant haematological cell lines Figure 1
Expression of SSTRs and opioid receptors in malignant haematological cell lines. A-F, RNAs were extracted from 
various hemopathy cell lines, reverse transcribed, and cDNAs encoding for SSTR1 to 5 were amplified by PCR. PCR products 
were separated on agarose gel and stained with ethidium bromide. St: 100 pb ladder, 1: Jurkat, 2: Nalm6, 3: RPMI-8226, 4: 
Ramos, 5: MCF-7, 6: NCI-H929, 7: LP-1, 8: SH-SY5Y, 9: 697, 10: U266, C: negative control. * corresponds to the band of the 
expected size. G, opioid receptors (KOP-, DOP- and MOP-R) were amplified by PCR. St: 100 pb ladder, 1: U266, 2: SH-SY5Y, 
C: negative control. H, expression of opioid receptors (KOP-, DOP- and MOP-R) was studied by western-blot in U266 cells 
(lane 1) and in positive controls (lane 2): human placenta (KOP-R), SH-SY5Y (MOP-R) and SK-N-BE cells (DOP-R). Data are 
representative of three independent experiments.
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Effects of Sst and Oct on cell cycle distribution in U266 
cells
We confirmed by using an alternative method, that SSTR
agonists were ineffective to regulate U266 cell prolifera-
tion. Distribution in the cell cycle of control or agonist-
pretreated U266 cells was determined after PI staining by
flow cytometry. A low (10 nM) or a high concentration
(10 μM) of Sst or Oct alone, or in combination with Css
were selected and cells were exposed during 24, 48 or 72
h. A representative experiment is depicted in the Figure 3
showing that neither Sst (10 μM) nor Oct (10 μM) were
able to promote changes in cell cycle distribution com-
pared to control cells after 72 h. Similar data were
obtained for 24 and 48 h pretreatment (data not shown).
The percentage of each phase was determined for control
or agonist-pretreated cells and these data are summarised
in the Table 3.
Effect of somatostatin and opioid receptors activation on 
apoptosis
Previous studies demonstrated that Sst analogs induced
apoptosis in several cell models [35-38]. As MM cells are
characterised by apoptosis resistance (see for review [39]),
we aimed to explore whether Sst or Oct would sensitise
the extrinsic cell death pathway. U266 cells were incu-
bated for 24, 48 or 72 h with 0.1 mg/mL of the agonistic
Fas antibody 7C11 alone or in combination with SSTR lig-
ands. In 7C11-treated cells and after 72 h pretreatment,
we observed a significant increase in sub-G1 cell popula-
tion indicating the occurrence of apoptosis that was asso-
ciated with a reduction of the G0-G1 fraction (Figure 4
Effect of Sst, Oct and Morph on U266 cell line viability Figure 2
Effect of Sst, Oct and Morph on U266 cell line viability. Exponentially growing cells were seeded and incubated for 24, 
48 or 72 h with (A) somatostatin (Sst), (B) octreotide (Oct), (C) Sst alone or combined with 10 μM morphine (Morph). The 
SSTR antagonist cyclosomatostatin (Css) was also included. U266 cell viability was determined using the XTT assay and data 
were normalized to absorbance values obtained in control cells. Data are mean ± S.E.M of 5 to 7 different experiments per-
formed in triplicate.Journal of Experimental & Clinical Cancer Research 2009, 28:77 http://www.jeccr.com/content/28/1/77
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and Table 3). Combination of the 7C11 antibody with Sst,
Oct, or Css did not produce additional change compared
to 7C11-treated cells (Table 3). Identical results were
obtained upon 24 and 48 h exposure but with a less
marked effect of 7C11 (data not shown).
U266 apoptosis was quantified using annexin V-FITC and
PI staining by flow cytometry. When cells were treated for
72 h in the presence of Sst, Oct or Css alone or in combi-
nation, no significant modification of the percentage of
viable (annexin V-/PI-), necrotic (annexin V-/PI+), early
apoptotic (annexin V+/PI-) or late apoptotic cells (annexin
V+/PI+) could be detected compared to control U266 cells
(Figure 4). In contrast, 7C11 was able to promote apopto-
sis as shown by an increase of both annexin V+/PI- and
annexin V+/PI+ cells with a concomitant reduction of via-
ble cells (Figure 4). When we assessed the combination of
7C11 with Sst or Oct, alone or associated with Css, no fur-
ther modulation of apoptosis could be observed (data not
shown).
Discussion
SSTRs are widely expressed within the central nervous sys-
tem, the endocrine system, the gastro-intestinal tract (see
for review [40]) but also in immune cells (see for review
[9]). Normal B and T cells were reported to exclusively
express SSTR3 [13]. In the current study, we observed that
all human MM cell lines express the five SSTR subtypes.
Our data are in agreement with those obtained by Georgii-
Hemming and collaborators [41] who observed only the
expression of SSTR2, 3 and 5 by using binding and RT-
PCR experiments. We also confirmed in binding studies
using [125 I-Tyr0] somatostatin that U266 cells express a
substantial amount of SSTRs. The different patterns of
SSTRs expression between malignant and non-tumoral B
cells suggest that these GPCRs would play a role in onco-
genesis or would be a specific marker of malignant hemo-
pathies. This hallmark is not restricted to B cells as we also
noticed that the human T cell leukaemia Jurkat expresses
the five different SSTR subtypes while SSTR3 is mainly
found in normal T lymphocytes [13]. We also found that
pre-B cells (Nalm-6 and 697), a B-cell lymphoma
(Ramos) and MM cell lines (LP-1, RPMI, U266 and NCI-
H929) express also the five different SSTR subtypes. This
suggests that a) the SSTRs expression is found along the B
cell differentiation stages b) SSTRs expression is not mod-
ulated during this process b) SSTRs expression pattern is
not a marker for B cell differentiation.
Sst and its analogs have been demonstrated to negatively
regulate tumor cell proliferation (see for review [42]) and
have been used in inoperable patients where neuroendo-
crine tumours stabilization or shrinkage can be obtained
[43]. However, in other cancers such as hepatocellular car-
Table 3: Cell cycle distribution of U266 MM cell line treated with SSTR ligands and 7C11
Treatment G0-G1 (%) S (%) G2-M (%) Sub-G1 (%)
Control 56,6 ± 3,0 25,1 ± 2,3 12,4 ± 1,1 2,5 ± 0,3
Sst 10 μM 57,4 ± 2,0 26,3 ± 0,8 9,6 ± 1,8 3,3 ± 0,2
Css 10 μM 60,8 ± 2,4 20,7 ± 2,4 11,2 ± 0,1 3,7 ± 0,8
Sst 10 μM/Css 10 μM 57,3 ± 2,2 26,2 ± 0,9 10,0 ± 2,5 2,9 ± 0,4
7C11 39,9 ± 1,5* 26,8 ± 1,1 9,9 ± 1,0 16,0 ± 0,9*
7C11/Sst 10 μM 40,3 ± 1,8* 27,2 ± 0,4 8,6 ± 1,1 14,0 ± 0,7*
7C11/Sst 10 μM/Css 10 μM 38,3 ± 3,3* 27,3 ± 1,0 8,9 ± 0,8 12,0 ± 1,1*
Oct 10 μM 55,2 ± 4,6 25,1 ± 3,5 13,6 ± 1,5 3,0 ± 0,5
Oct 10 μM/Css 10 μM 55,6 ± 4,7 24,9 ± 3,6 12,6 ± 1,6 4,0 ± 0,8
7C11/Oct 10 μM 43,1 ± 0,5* 27,2 ± 1,7 12,2 ± 1,5 13,6 ± 1,9*
7C11/Oct 10 μM/Css 10 μM 41,9 ± 0,8* 26,4 ± 2,6 8,1 ± 0,4 18,2 ± 4,6*
U266 cells were pretreated or not (control) with Sst, Oct, Css or the agonistic Fas antibody 7C11 (7C11) for 72 h. Cells were stained with PI, 
analyzed by flow cytometry and each fraction of the cell cycle was determined using Wincycle®. Data are mean ± S.E.M. of 3 independent 
experiments. *, ANOVA followed by Bonferroni-Dunn (p < 0.05), statistically significant differences compared to control cells.Journal of Experimental & Clinical Cancer Research 2009, 28:77 http://www.jeccr.com/content/28/1/77
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cinoma, the clinical benefit of Oct is not evidenced even
in positive Oct scintigraphy patients [44]. To our knowl-
edge, only one study examined the effects of Sst and Oct
in MM cell lines and showed a strong decrease of viable
cells after 48 h Oct exposure [41]. This is in marked con-
trast with our data since either Sst or Oct were unable to
affect cell proliferation of the U266 cell line. Such discrep-
ancies should be explained by the use of different clones
of the U266. We can also hypothesize that our U266 cells
would express SSTRs with opposite effects on prolifera-
tion. SSTR2 and 5 were reported to inhibit cell prolifera-
tion by phosphotyrosine phosphatase (PTP) activation
and inhibition of calcium channels, respectively [42,45].
In contrast, SSTR4 were shown to activate the MAPK cas-
cade and promoting proliferation [46]. So, no effect on
proliferation would be observed upon co-activation of
those SSTRs. Discrepancies between our study and the one
of Georgii-Hemming and collaborators [41] about cellu-
lar viability should also be due to the presence or the
absence of serum in the culture medium. However, we can
rule out such explanation since we observed no effect
upon SSTR agonists when experiments were conducted in
serum-free culture medium (data not shown).
Anti-tumoral activity of Sst or its analogs are also due to
pro-apoptotic effects (see for review [47]). In two MM cell
lines U266 (current study) and LP-1 (data not shown), we
observed that neither Sst nor Oct promote apoptosis in
our experimental conditions. This was illustrated by the
lack of sub-G1 peak in cell cycle assay and the absence of
labelling in annexin V/PI experiments. In contrast,
Georgii-Hemming et al. showed that in three MM cells
(HL-407L, HL-407E and U-1958) Oct induced a weak
increase in annexin V/PI staining suggesting that SSTRs
Cell cycle distribution of U266 cells after SSTR stimulation Figure 3
Cell cycle distribution of U266 cells after SSTR stimulation. Exponentially growing cells were incubated with 10 μM 
Sst or Oct, or with 0.1 mg/mL 7C11 (agonistic Fas antibody) for 72 h. DNA content analysis was done after PI staining of eth-
anol-permeabilized cells. % of each cell cycle phase are summarized in the Table 2. Data shown are representative of 3 inde-
pendent experiments.Journal of Experimental & Clinical Cancer Research 2009, 28:77 http://www.jeccr.com/content/28/1/77
Page 9 of 11
(page number not for citation purposes)
could promote apoptosis [41] but the U266 cell line was
not investigated. Sharma et al. first described the role of
SSTR3 in apoptosis when expressed in Chinese hamster
ovary cells and demonstrated that Oct promotes dephos-
phorylation of wild-type p53 which leads to DNA frag-
mentation [35]. Even in the absence of apoptosis, we can
not rule out that SSTRs are not coupled to apoptotic path-
ways since U266 was shown to express the anti-apoptotic
protein Bcl-2 [48].
MM cells were reported to express death receptors, includ-
ing Fas (CD95), which triggers extrinsic apoptotic path-
way [49]. When activated by the agonistic Fas antibody
7C11, this receptor produces apoptosis. After activation of
SSTRs either by the endogenous agonist or Oct, we were
unable to detect any enhancement of Fas-induced apopto-
sis. This is in contrast with previous data obtained in the
pancreatic cancer BxPC-3 cells [50]. Indeed, SSTR2 was
shown to up-regulate TNF-related apoptosis-inducing lig-
and (TRAIL) receptors, DR4 and TNFRI that trigger death
first, by activating caspase 8 and second by down-regulat-
ing the anti-apoptotic mitochondrial protein Bcl2.
Opioid receptors are also expressed in immune cells [51]
in which they promote apoptosis by regulating Fas expres-
sion [31]. These GPCRs were shown to heterodimerize
with SSTRs [52] and we hypothesized that co-treatment
with opioids and Sst or Oct would activate signalling
pathways leading to apoptosis. In the current study, we
demonstrated by molecular experiments and western blot
that U266 cells express MOP-R that are able to bind a pro-
totypical ligand [3H]diprenorphine. When morphine (a
MOP-R "selective" agonist) was used alone, no evidence
for apoptosis was detected. Similar results were obtained
Apoptosis study of U266 cells after SSTR and Fas receptor activation Figure 4
Apoptosis study of U266 cells after SSTR and Fas receptor activation. Exponentially growing cells were incubated 
with 10 μM Sst, Oct, Css alone or combinated, or with 0.1 mg/mL 7C11 (agonistic Fas antibody) for 72 h. Cells were stained 
with annexinV-FITC and PI and analyzed by fluorescence-activated cell sorting to quantify apoptosis. Data shown are repre-
sentative of 6 independent experiments.Journal of Experimental & Clinical Cancer Research 2009, 28:77 http://www.jeccr.com/content/28/1/77
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when both opioid and somatostatin receptors were co-
activated. While morphine and ethylketocyclazocine were
reported to interact with SSTRs in the opposum kidney
cells and HepG2 cell line, respectively, and promote cell
growth inhibition [53,54], our data rule out such conclu-
sions in our cellular model.
Conclusion
In conclusion, we demonstrated that the human MM cell
line U266 expresses both SSTRs and the MOP-R. How-
ever, their stimulation by Sst, Oct or morphine alone or in
combination fails to induce cell cycle modifications and
apoptosis in U266 cells. While we demonstrated that Oct
has no effect on the myeloma cell lines U266 and LP-1
(data not shown), we can not exclude that such targeted
treatment would be ineffective in patients.
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